SCHEMBL6319280

SCHEMBL6319280

Cc1cc(C(=O)O)c(/C=C2\C(=O)Nc3cccc(-c4ccc(F)c(Cl)c4)c32)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 8/20 0.43
KDR P35968 6/20 0.43
RET P07949 4/20 0.43
FLT1 P17948 3/20 0.43
CSF1R P07333 2/20 0.43
FGFR1 P11362 2/20 0.43
SRC P12931 2/20 0.43
FGFR3 P22607 2/20 0.43
MAPK1 P28482 2/20 0.43
FLT4 P35916 2/20 0.43
FLT3 P36888 2/20 0.43
PDGFRB P09619 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
GMNN O75496 1/20 0.43
USP2 O75604 1/20 0.43
ABL1 P00519 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
KIT P10721 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319282 1.00 ALK (0.43) ALKKDRRETFLT1CSF1R
SCHEMBL6322327 0.90 ALK (0.48) ALKKDRRETFLT1CSF1R
SCHEMBL6319389 0.89 ALK (0.48) ALKKDRRETFLT1CSF1R
SCHEMBL6319385 0.89 ALK (0.48) ALKKDRRETFLT1CSF1R
SCHEMBL6321849 0.88 ALK (0.48) ALKKDRRETFLT1CSF1R
SCHEMBL6321854 0.88 ALK (0.48) ALKKDRRETFLT1CSF1R
SCHEMBL6319360 0.87 ALK (0.48) ALKKDRRETFLT1CSF1R
SCHEMBL6324913 0.87 FLT1 (0.43) ALKKDRRETFLT1CSF1R
SCHEMBL6321109 0.86 KDR (0.45) ALKKDRRETFLT1CSF1R
SCHEMBL6327818 0.86 ALK (0.47) ALKKDRRETFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 ALK 1015/4885KDR 819/4885RET 658/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 ALK 1015/4885KDR 819/4885RET 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.